Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01183533 · ClinicalTrials.gov registry record · Phase 2
Safety of Intravenous Thrombolysis for Wake-up Stroke
A Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT01183533 is a Phase 2 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 40 participants.
The verdict
NCT01183533, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose is to demonstrate the safety of intravenous tissue plasminogen activator (IV t-PA) in ischemic stroke patients who present to the emergency department (ED) after awakening with the symptoms of suspected ischemic stroke.
Interventions
- DRUG Alteplase (iv t-PA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2010-07 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01183533
The ClinicalTrials.gov registry entry for NCT01183533 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alteplase (iv t-PA) is the first listed.
NCT01183533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01183533 about?
NCT01183533 is a clinical study titled "Safety of Intravenous Thrombolysis for Wake-up Stroke". The purpose is to demonstrate the safety of intravenous tissue plasminogen activator (IV t-PA) in ischemic stroke patients who present to the emergency department (ED) after awakening with the symptoms of suspected ischemic stroke.
What is the current status of trial NCT01183533?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2010-07. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01183533?
The interventions under investigation include: Alteplase (iv t-PA) (DRUG).
Who is sponsoring clinical trial NCT01183533?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.